Testosterone Cream Concentration for Daily Application
For testosterone replacement therapy in hypogonadal men, the appropriate testosterone cream concentrations are 1% gel (50-100 mg daily) or 2% gel (10-70 mg daily depending on formulation), with 1.62% gel being FDA-approved at starting doses of 40.5 mg daily. 1, 2
FDA-Approved Formulations and Dosing
The FDA-approved testosterone gel formulations provide clear guidance on appropriate concentrations:
1.62% Testosterone Gel (FDA-Approved)
- Starting dose: 40.5 mg testosterone daily (2 pump actuations or one 40.5 mg packet) 2
- Dose range: 20.25-81 mg daily
- Application site: Upper arms and shoulders only
- Titration: Based on pre-dose morning testosterone levels at 14 and 28 days
- Target serum level: 350-750 ng/dL 2
1% Testosterone Gels (Multiple Brands)
- Typical dose: 50-100 mg daily 1
- Application sites: Back, abdomen, upper thighs, and upper arms
- Advantages: Easy application, good skin tolerability 1
2% Testosterone Formulations
- Axiron 2% solution: 30-120 mg daily (applied to axilla) 1
- Fortesta 2% gel: 10-70 mg daily (applied to front and inner thighs) 1
Clinical Monitoring Requirements
The Endocrine Society guidelines 3, 4 specify rigorous monitoring:
- Initial assessment: 3-6 months after starting therapy
- Testosterone monitoring: Measure levels to achieve mid-normal range (approximately 500-600 ng/dL) 1
- Timing of blood draw:
- Hematocrit monitoring: Baseline, 3-6 months, then annually; stop if >54% 3, 4
- PSA monitoring: For men ≥40 years with baseline PSA >0.6 ng/mL 3
Application Site Matters for Safety
Critical safety consideration: Application site significantly affects both efficacy and transfer risk 5, 6:
- Upper arms/shoulders: 30-40% higher bioavailability compared to abdomen 6
- Abdomen: Lower bioavailability but may reduce transfer risk 5
- Transfer prevention: Cover application site with clothing or wash site before skin-to-skin contact 3, 2, 5
- Avoid swimming/showering: For minimum 2 hours after application 2
Special Populations and Lower Doses
Recent evidence suggests flexibility in dosing for specific populations:
Non-Binary/Gender-Diverse Individuals
- Lower doses: <50 mg daily of 1% gel or <100 mg daily of 5% cream can be effective 7, 8
- Achieved testosterone levels: Median 11-12 nmol/L (approximately 317-346 ng/dL) 7, 8
- Continuation rates: 87% remained on low-dose therapy at 12+ months 7
Dose Fractionation
- Twice-daily dosing: May reduce peak-trough fluctuations while maintaining same total daily dose 9
- Improved target achievement: 83% vs 33% achieving target levels with fractionated dosing 9
Common Pitfalls to Avoid
Secondary exposure risk: The FDA mandates a boxed warning about virilization in children and women exposed to unwashed application sites 2. Patients must cover sites with clothing and wash hands thoroughly.
Application site errors: Do NOT apply to genitals, chest, armpits, or knees 2. The 1.62% formulation is specifically approved only for upper arms/shoulders.
Inadequate monitoring: Failure to check testosterone levels at appropriate intervals can result in subtherapeutic or supratherapeutic dosing 3, 4.
Cardiovascular considerations: While controversial, transdermal preparations may have more stable testosterone levels compared to injections, potentially reducing cardiovascular risk 1.
Product interchangeability: Different testosterone gel concentrations and formulations are NOT interchangeable 2. Each has specific dosing and application instructions.
Practical Algorithm for Initiation
- Confirm diagnosis: Two morning testosterone levels below normal range 2
- Start with FDA-approved formulation: 1.62% gel at 40.5 mg daily OR 1% gel at 50 mg daily 1, 2
- Check testosterone at 14 and 28 days: Adjust dose to achieve 350-750 ng/dL 2
- Monitor hematocrit at 3-6 months: Stop if >54% 3, 4
- Reassess symptoms and labs at 3-6 months: Then annually 3, 4